Sokhal, Ashok Kumar; Sankhwar, Satyanarayan; Goel, Apul; Singh, Kawaljit; Kumar, Manoj; Purkait, Bimalesh; Saini, Durgesh Kumar (August 30, 2017). "A Prospective Study to Evaluate Sexual Dysfunction and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Benign Prostatic Hyperplasia by Alpha Blockers". Urology. 118: 92–97. doi:10.1016/j.urology.2017.08.025. PMID28860050. S2CID36531385.
Stanaszek, W. F.; Kellerman, D.; Brogden, R. N.; Romankiewicz, J. A. (April 1983). "Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure". Drugs. 25 (4): 339–384. doi:10.2165/00003495-198325040-00002. ISSN0012-6667. PMID6303744. S2CID46973044.
Roehrborn, Claus G.; Siami, Paul; Barkin, Jack; Damião, Ronaldo; Major-Walker, Kim; Morrill, Betsy; Montorsi, Francesco (February 1, 2008). "The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study". The Journal of Urology. 179 (2): 616–621. doi:10.1016/j.juro.2007.09.084. PMID18082216.
Searle, M.; Dathan, R.; Dean, S.; Christensen, C. C.; Westheim, A. (1990). "Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial". European Journal of Clinical Pharmacology. 39 (3): 299–300. doi:10.1007/BF00315116. PMID2147909. S2CID6750811.
Pool, J. L. (1991). "Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials". American Heart Journal. 122 (3 Pt 2): 926–931. doi:10.1016/0002-8703(91)90813-w. PMID1678924.
Holtzman, J. L.; Kaihlanen, P. M.; Rider, J. A.; Lewin, A. J.; Spindler, J. S.; Oberlin, J. A. (March 1988). "Concomitant administration of terazosin and atenolol for the treatment of essential hypertension". Archives of Internal Medicine. 148 (3): 539–543. doi:10.1001/archinte.1988.00380030045010. PMID3277569.
Holtzman, J. L.; Kaihlanen, P. M.; Rider, J. A.; Lewin, A. J.; Spindler, J. S.; Oberlin, J. A. (1988). "Concomitant administration of terazosin and atenolol for the treatment of essential hypertension". Archives of Internal Medicine. 148 (3): 539–543. doi:10.1001/archinte.1988.00380030045010. PMID3277569.
Franco-Salinas, Gabriela; de la Rosette, Jean J. M. C. H.; Michel, Martin C. (March 2010). "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations". Clinical Pharmacokinetics. 49 (3): 177–188. doi:10.2165/11317580-000000000-00000. ISSN1179-1926. PMID20170206. S2CID207298067.
Roehrborn, C. G. (December 2001). "Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker". Urology. 58 (6 Suppl 1): 55–63, discussion 63–64. doi:10.1016/s0090-4295(01)01322-x. ISSN1527-9995. PMID11750253.
Nomiya, M; Yamaguchi, O (2003). "A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders". J Urol. 170 (2 Pt 1): 649–653. doi:10.1097/01.ju.0000067621.62736.7c. PMID12853849.
Giardina, Dario; Gulini, Ugo; Massi, Maurizio; Piloni, Maria G.; Pompei, Pierluigi; Rafaiani, Giovanni; Melchiorre, Carlo (March 1, 1993). "Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on .alpha.-blocking activity". Journal of Medicinal Chemistry. 36 (6): 690–698. doi:10.1021/jm00058a005. ISSN0022-2623. PMID8096245.
Campbell, Simon F.; Hardstone, J. David; Palmer, Michael J. (May 1, 1988). "2,4-Diamino-6,7-dimethoxyquinoline derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents". Journal of Medicinal Chemistry. 31 (5): 1031–1035. doi:10.1021/jm00400a025. ISSN0022-2623. PMID2896245.
Ruffolo, Robert R.; Bondinell, William; Hieble, J. Paul (September 1, 1995). ".alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications". Journal of Medicinal Chemistry. 38 (19): 3681–3716. doi:10.1021/jm00019a001. ISSN0022-2623. PMID7562902.
Sokhal, Ashok Kumar; Sankhwar, Satyanarayan; Goel, Apul; Singh, Kawaljit; Kumar, Manoj; Purkait, Bimalesh; Saini, Durgesh Kumar (August 30, 2017). "A Prospective Study to Evaluate Sexual Dysfunction and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Benign Prostatic Hyperplasia by Alpha Blockers". Urology. 118: 92–97. doi:10.1016/j.urology.2017.08.025. PMID28860050. S2CID36531385.
Stanaszek, W. F.; Kellerman, D.; Brogden, R. N.; Romankiewicz, J. A. (April 1983). "Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure". Drugs. 25 (4): 339–384. doi:10.2165/00003495-198325040-00002. ISSN0012-6667. PMID6303744. S2CID46973044.
Roehrborn, Claus G.; Siami, Paul; Barkin, Jack; Damião, Ronaldo; Major-Walker, Kim; Morrill, Betsy; Montorsi, Francesco (February 1, 2008). "The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study". The Journal of Urology. 179 (2): 616–621. doi:10.1016/j.juro.2007.09.084. PMID18082216.
Searle, M.; Dathan, R.; Dean, S.; Christensen, C. C.; Westheim, A. (1990). "Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial". European Journal of Clinical Pharmacology. 39 (3): 299–300. doi:10.1007/BF00315116. PMID2147909. S2CID6750811.
Pool, J. L. (1991). "Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials". American Heart Journal. 122 (3 Pt 2): 926–931. doi:10.1016/0002-8703(91)90813-w. PMID1678924.
Holtzman, J. L.; Kaihlanen, P. M.; Rider, J. A.; Lewin, A. J.; Spindler, J. S.; Oberlin, J. A. (March 1988). "Concomitant administration of terazosin and atenolol for the treatment of essential hypertension". Archives of Internal Medicine. 148 (3): 539–543. doi:10.1001/archinte.1988.00380030045010. PMID3277569.
Holtzman, J. L.; Kaihlanen, P. M.; Rider, J. A.; Lewin, A. J.; Spindler, J. S.; Oberlin, J. A. (1988). "Concomitant administration of terazosin and atenolol for the treatment of essential hypertension". Archives of Internal Medicine. 148 (3): 539–543. doi:10.1001/archinte.1988.00380030045010. PMID3277569.
Franco-Salinas, Gabriela; de la Rosette, Jean J. M. C. H.; Michel, Martin C. (March 2010). "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations". Clinical Pharmacokinetics. 49 (3): 177–188. doi:10.2165/11317580-000000000-00000. ISSN1179-1926. PMID20170206. S2CID207298067.
Roehrborn, C. G. (December 2001). "Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker". Urology. 58 (6 Suppl 1): 55–63, discussion 63–64. doi:10.1016/s0090-4295(01)01322-x. ISSN1527-9995. PMID11750253.
Nomiya, M; Yamaguchi, O (2003). "A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders". J Urol. 170 (2 Pt 1): 649–653. doi:10.1097/01.ju.0000067621.62736.7c. PMID12853849.
Chapple, C. R. (1996). "Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience". European Urology. 29 (2): 129–144. ISSN0302-2838. PMID8647139.
Mathur, R. P.; Nayak, Sumanlata; Sivaramakrishnan, R.; Jain, Vikas (September 2014). "Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia". The Journal of the Association of Physicians of India. 62 (9 Suppl): 40–44. ISSN0004-5772. PMID26245042.
Giardina, Dario; Gulini, Ugo; Massi, Maurizio; Piloni, Maria G.; Pompei, Pierluigi; Rafaiani, Giovanni; Melchiorre, Carlo (March 1, 1993). "Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on .alpha.-blocking activity". Journal of Medicinal Chemistry. 36 (6): 690–698. doi:10.1021/jm00058a005. ISSN0022-2623. PMID8096245.
Campbell, Simon F.; Hardstone, J. David; Palmer, Michael J. (May 1, 1988). "2,4-Diamino-6,7-dimethoxyquinoline derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents". Journal of Medicinal Chemistry. 31 (5): 1031–1035. doi:10.1021/jm00400a025. ISSN0022-2623. PMID2896245.
Ruffolo, Robert R.; Bondinell, William; Hieble, J. Paul (September 1, 1995). ".alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications". Journal of Medicinal Chemistry. 38 (19): 3681–3716. doi:10.1021/jm00019a001. ISSN0022-2623. PMID7562902.
Sokhal, Ashok Kumar; Sankhwar, Satyanarayan; Goel, Apul; Singh, Kawaljit; Kumar, Manoj; Purkait, Bimalesh; Saini, Durgesh Kumar (August 30, 2017). "A Prospective Study to Evaluate Sexual Dysfunction and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Benign Prostatic Hyperplasia by Alpha Blockers". Urology. 118: 92–97. doi:10.1016/j.urology.2017.08.025. PMID28860050. S2CID36531385.
Stanaszek, W. F.; Kellerman, D.; Brogden, R. N.; Romankiewicz, J. A. (April 1983). "Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure". Drugs. 25 (4): 339–384. doi:10.2165/00003495-198325040-00002. ISSN0012-6667. PMID6303744. S2CID46973044.
Searle, M.; Dathan, R.; Dean, S.; Christensen, C. C.; Westheim, A. (1990). "Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial". European Journal of Clinical Pharmacology. 39 (3): 299–300. doi:10.1007/BF00315116. PMID2147909. S2CID6750811.
Franco-Salinas, Gabriela; de la Rosette, Jean J. M. C. H.; Michel, Martin C. (March 2010). "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations". Clinical Pharmacokinetics. 49 (3): 177–188. doi:10.2165/11317580-000000000-00000. ISSN1179-1926. PMID20170206. S2CID207298067.
Stanaszek, W. F.; Kellerman, D.; Brogden, R. N.; Romankiewicz, J. A. (April 1983). "Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure". Drugs. 25 (4): 339–384. doi:10.2165/00003495-198325040-00002. ISSN0012-6667. PMID6303744. S2CID46973044.
Franco-Salinas, Gabriela; de la Rosette, Jean J. M. C. H.; Michel, Martin C. (March 2010). "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations". Clinical Pharmacokinetics. 49 (3): 177–188. doi:10.2165/11317580-000000000-00000. ISSN1179-1926. PMID20170206. S2CID207298067.
Roehrborn, C. G. (December 2001). "Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker". Urology. 58 (6 Suppl 1): 55–63, discussion 63–64. doi:10.1016/s0090-4295(01)01322-x. ISSN1527-9995. PMID11750253.
Chapple, C. R. (1996). "Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience". European Urology. 29 (2): 129–144. ISSN0302-2838. PMID8647139.
Mathur, R. P.; Nayak, Sumanlata; Sivaramakrishnan, R.; Jain, Vikas (September 2014). "Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia". The Journal of the Association of Physicians of India. 62 (9 Suppl): 40–44. ISSN0004-5772. PMID26245042.
Giardina, Dario; Gulini, Ugo; Massi, Maurizio; Piloni, Maria G.; Pompei, Pierluigi; Rafaiani, Giovanni; Melchiorre, Carlo (March 1, 1993). "Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on .alpha.-blocking activity". Journal of Medicinal Chemistry. 36 (6): 690–698. doi:10.1021/jm00058a005. ISSN0022-2623. PMID8096245.
Campbell, Simon F.; Hardstone, J. David; Palmer, Michael J. (May 1, 1988). "2,4-Diamino-6,7-dimethoxyquinoline derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents". Journal of Medicinal Chemistry. 31 (5): 1031–1035. doi:10.1021/jm00400a025. ISSN0022-2623. PMID2896245.
Ruffolo, Robert R.; Bondinell, William; Hieble, J. Paul (September 1, 1995). ".alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications". Journal of Medicinal Chemistry. 38 (19): 3681–3716. doi:10.1021/jm00019a001. ISSN0022-2623. PMID7562902.